The pharmacology of SR 141716A: A review

CNS Drug Reviews

Volumn 5, Issue 1, 1999, Pages 43-58

  Nakamura Palacios, E M ^a   Moerschbaecher, J M ^b   Barker, L A ^b,c  

^a FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LSU SD   (United States)

Author keywords

Cannabinoid agonists; Cannabinoid antagonists; Cannabinoid receptors; CB1; CB2; Marijuana; SR 141716A N (piperidinyl yl) 5 (4 chlorophenyl) 1 (2,4 dichlorophenyl) 4 methyl 1H pyrazole 3 carboxamidehydrochloride; 9 THC ( 9 Tetrahydrocannabinol)

Indexed keywords

ATROPINE; CANNABINOID; IMIDAZOLINE RECEPTOR; NEUROPEPTIDE Y; RIMONABANT; SCOPOLAMINE; TETRAHYDROCANNABINOL;

CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; MEMORY; NONHUMAN; RECEPTOR BINDING; REVIEW; WITHDRAWAL SYNDROME;

EID: 0032886498     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1999.tb00085.x     Document Type: Review

References (99)

1. Abood ME, Martin BR. Molecular neurobiology of the cannabinoid receptor. Int Rev Neurobiol 1996;39:197-221.
2. 9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996;278:1290-1295.
3. Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 1998;284:1209-1217.
4. Anderson PO, McGuire GG. Delta-9-tetrahydrocannabinol as an antiemetic. Am J Hosp Pharm 1981;38:639-646.
5. Annas GJ. Reefer madness - the federal response to California's medical-marijuana law. N Engl J Med 1997;337(6):435-439.
6. 1) receptors. Psychopharmacology 1997;132:104-106.
7. Barth F. Cannabinoid receptor agonists and antagonists. Exp Opin Ther Patents 1998;8:301-313.
8. Beardsley PM, Scimeca JA, Martin BR. Studies on the agonistic activity of delta-9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 1987;241:521-526.
9. 1 induces krox-24 expression in human astrocytoma cells. J Biol Chem 1995;270:13973-13980.
10. Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997;272:22330-22339.
11. 1. Biochem J 1995;312:637-641.
12. 2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem 1996;237:704-711.
13. Breivogel CS, Sim JL, Childers SR. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J Pharmacol Exp Ther 1998;282:1632-1642.
14. Brodkin J, Moerchbaecher JM. SR 141716A antagonizes the disruptive effects of cannabinoid ligands on learning in rats. J Pharmacol Exp Ther 1997;282:1526-1532.
15. 1 receptor agonists in the mouse brain. Eur J Pharmacol 1997;336:295-298.
16. Calignano A, La Ran G, Beltramo M, Makriyannis A, Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol 1997;337(1):R1-R2.
17. Chidiac P. Receptor state and ligand efficacy. Trends Pharmacol Sci 1995;16:83-84.
18. Childers SR, Breivogel CS. Cannabis and endogenous cannabinoid system. Drug Alcohol Depend 1998;51:173-187.
19. Compton DR, Martin BR. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J. Pharmacol Exp Ther 1997;283(3):1138-1143.
20. 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996;227:586-594.
21. Coutts AA, Pertwee RG. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br J Pharmacol 1997;121:1557-1566.
22. Devane WA, Dysarz FA, III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-613.
23. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.
24. Devane WA. New dawn of cannabinoid pharmacology. Trends Pharmacol Sci 1994;15:40-41.
25. Dewey WL. Cannabinoid Pharmacology. Pharmacol Rev 1986;38:151-178.
26. 2 receptors. Mol Pharmacol 1995;48:443-450.
27. Fernando SR, Pertwee RG. Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist. Br J Pharmacol 1997;121:1716-1720.
28. 1 but not opioid receptors. Neurosci Lett 1997;226:159-162.
29. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-1647.
30. Gifford AN, Ashby CR, Jr. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J Pharmacol Exp Ther 1996;277:1431-1436.
31. Gifford AN, Samiian L, Gatley SJ, Ashby CR, Jr. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. Eur J Pharmacol 1997;324:187-192.
32. 35S]Thio)-triphosphate binding assay in rat cerebellar membranes. J Pharmacol Exp Ther 1998;285:553-560.
33. Herkenham M, Lynn AB, Johnson MR, Melvin LS, Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 1991;11:563-583.
34. Herkenham M. Cannabinoid receptor localization in brain: relationship to motor and reward system. Ann N Y Acad Sci 1992;654:19-32.
35. 1 receptor using SR 141716A, a central cannabinoid receptor antagonist. Neurosci Lett 1996;220:101-104.
36. Howlett AC, Flemming RM. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984;36:532-538.
37. 1-adrenergic receptor subtypes identify critical residues that modulate active state isomerization. J Biol Chem 1996;271:7956-7964.
38. Kenakin T. Efficacy as a molecular property of a ligand. Trends Pharmacol Sci 1995;16:84-85.
39. Kenakin T. The classification of seven transmembrane receptors in cellular expression systems. Pharmacol Rev 1996;36:413-463.
40. Kenakin T. Pharmacological Analysis of Drug-Receptor Interaction. New York: Raven Press, 1997.
41. 1-like cannabinoid receptors. J Pharmacol Exp Ther 1997;281:1030-1037.
42. 1 receptor. Eur J Pharmacol 1997;334:R1-R2.
43. Lewis DL, Pan X. An inverse agonist can reverse the tonic activity of the neuronal cannabinoid receptor. Pharmacologist 1998;39:308.
44. 9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 1996;126:125-131.
45. Lichtman AH, Martin BR. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav 1997;57:7-12.
46. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glial cells. Proc Natl Acad Sci USA 1992;89:3825-3829.
47. 2 receptors. Br J Pharmacol 1998;124:619-622.
48. Mailleux P, Vanderhaeghen J-J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography in situ hybridization histochemistry. Neuroscience 1992;48:655-668.
49. 9-tetrahydrocannabinol-induced memory impairment by the cannabinoid antagonist SR 141716A. 27th Annual Meeting Society for Neuroscience 1997;23:2382.
50. 1 receptor antagonist SR 141716A on the behavior of pigeons and rats. Psychopharmacology 1996;124:315-322.
51. Martin BR, Welch SP, Abood M. Progress toward understanding the cannabinoid receptor and its second messenger system. Adv Pharmacol 1994;25:341-397.
52. Martin BR. Marijuana. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995:1757-1765.
53. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
54. Mechoulam R, Feigenbaum JJ. Towards cannabinoid drugs. Prog Med Chem 1987;24:159-207.
55. Mechoulam R, Hanus L, Fride E. Towards cannabinoid drugs - revisited. Prog Med Chem 1998;35:199-243.
56. Molderings GJ, Gothert M. Presynaptic imidazoline receptors mediate inhibition of noradrenaline release from sympathetic nerves in rat blood vessels. Fundam Clin Pharmacol 1998;12:388-397.
57. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-65.
58. 9-THC and scopolamine in squirrel monkeys. 27th Annual Meeting Society for Neuroscience 1997;23:1499.
59. 1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997;8:491-496.
60. Patrini G, Sacerdote P, Fuzio D, Manfredi B, Parolaro D. Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP 55,940, a synthetic cannabinoid compound. J Neuroimmunol 1997;80:143-148.
61. 1 receptors in mouse urinary bladder. Br J Pharmacol 1996;118:2035-2058.
62. 1 receptors in guinea-pig small intestine. Br J Pharmacol 1996;118:2199-2205.
63. Pertwee RG, Griffin G, Lainton JA, Huffman JW. Pharmacological characterization of cannabinoid receptor agonists in the mouse isolated vas deferens. Eur J Pharmacol 1995;284:241-247.
64. 2 receptors. Pharmacol Ther 1997;74:129-180.
65. Petitet F, Jeantaud B, Capet M, Doble A. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein. A radioligand binding study. Biochem Pharmacol 1997;54:1267-1270.
66. + channels. Neuropharmacology 1996;35:983-981.
67. Prescott WR, Gold LH, Martin BR. Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by delta 9-THC in the rat. Psychopharmacology (Berl.) 1992;107:117-124.
68. Razdan RK. Structure-activity relationships in cannabinoids: An overview. NIDA Res Monogr 1987;79:3-14.
69. Richardson JD, Aanonsen L, Hargreaves KM. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur J Pharmacol 1997;319:R3-R4.
70. Richardson JD, Aanonsen L, Hargreaves KM. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci 1998;18:451-457.
71. Rinaldi-Carmona M, Barth F, Héaulme M, et al. Biochemical and pharmacological characterisation of SR141617A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 1995;56:1941-1947.
72. Rinaldi-Carmona M, Barth F, Héaulme M, et al. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240-241.
73. 2 cannabinoid receptor. J Pharmacol Exp Ther 1998;284:644-650.
74. 1 cannabinoid receptor isoforms. J Pharmacol Exp Ther 1996;278:871-878.
75. 1) cannabinoid receptor antagonist, in rodent brain. Life Sci 1996;58:1239-1247.
76. Rubino T, Patrini G, Massi P, et al. Cannabinoid-precipitated withdrawal: A time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression. J Pharmacol Exp Ther 1998;285:813-819.
77. 2-adrenergic receptor Extending the ternary complex model. J Biol Chem 1993;268:4625-4636.
78. 1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci 1996;58:PL103-110.
79. Sañudo-Peña MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neurosci Lett 1997;223:125-128.
80. Schlicker E, Timm J, Göthert M. Cannabinoid receptor-mediated inhibition of dopamine release in the retina. Naunyn-Schmiedebergs Arch Pharmacol 1996;354:791-795.
81. 1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schimedeberg's Arch Pharmacol 1997;356:583-589.
82. 35S]thio)triphosphate binding in rat brain membranes. Life Sci 1996;59:659-668.
83. Shire D, Carillon C, Kaghad M, et al. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995;270:3726-3731.
84. Souilhac J, Poncelet M, Rinaldi-Carmona M, Fur GL, Soubrié P. Intrastriatal injection of cannabinoid receptor agonists induced turning behavior in mice. Pharmacol Biochem Behav 1995;51:3-7.
85. 1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 1996;126:165-172.
86. Tersigni TJ, Rosenberg HC. Local pressure application of cannabinoid agonists increases spontaneous activity of rat substantia nigra pars reticulata neurons without affecting response to iontophoretically-applied GABA. Brain Res 1996;733:184-192.
87. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 1995;280:R13-R15.
88. UK. Cannabis Information. Available at: http://www.ukcia/news/4/st2427. Accessed 1999.
89. Vivian JA, Kishioka S, Woods JH. Behavioral effects of the cannabinoid antagonist SR 141716A in rhesus monkeys. 27th Annual Meeting Society for Neuroscience 1997;23:1869.
90. Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Internal Med 1997;126:791-798.
91. 1 cannabinoid receptors in hemorrhagic shock. Nature 1997;390:518-521.
92. Weis JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model I. Model description. J Theor Biol 1996;178:151-167.
93. Weis JM, Morgan, PH, Lutz, MW, Kenakin TP. The cubic ternary complex receptor-occupancy model II. Understanding apparent affinity. J Theor Biol 1996;178:169-182.
94. Weis JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model III. Resurrecting efficacy. J Theor Biol 1996;181:381-397.
95. Welch SP, Huffman JW, Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR 141716A. J Pharmacol Exp Ther 1998;286:1301-1308.
96. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoid in rats. Neuropharmacology 1995;34:669-676.
97. 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 1995;275:1-6.
98. 9-THC on complex behavioral processes in monkeys. FASEB J 1997;A205.
99. 2-adrenergic receptor can modulate receptor/G-protein affinity. Mol Pharmacol 1998;53:524-529.